Rosetta Genomics Signs Two Deals for MicroRNA Tests
February 01, 2011
Rosetta Genomics Signs Two Deals for MicroRNA Tests
Rosetta signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Rosetta Releases miRview Kidney Test Validation Study, Anticipates Medicare Coverage Decision
April 4, 2013 / Gene Silencing News - Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012 / GenomeWeb Daily News - After Medicare Nod for CUP Diagnostic, Rosetta Aims to Get Coverage for Other miRNA Tests
May 24, 2012 / Gene Silencing News - Rosetta Genomics' 2011 Revenues Fall 63 Percent
April 2, 2012 / GenomeWeb Daily News - Rosetta Genomics Restructures, Eliminating 35 Positions
October 11, 2011 / GenomeWeb Daily News